Status:
COMPLETED
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
Brief Summary
Study to investigate the safety and efficacy information of Alesion® Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczem...
Eligibility Criteria
Inclusion
- All the patients who:
- haven't treatment experience of epinastine product;
- have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma
Exclusion
- Alesion® Tablet is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Tablet in package insert. However, it is unknown whether a patient is hypersensitive to the ingredients of the product in almost cases. And this survey is drug utilization study to observe actual use in any patients. Therefore exclusion criteria is not set in the protocol
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
2001 Patients enrolled
Trial Details
Trial ID
NCT02238223
Start Date
April 1 2004
Last Update
September 12 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.